Netherton Syndrome Pipeline Analysis, 2025 By Delveinsight Tennor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma

(MENAFN- GetNews)


"Netherton Syndrome Pipeline Analysis"DelveInsight's,“Netherton Syndrome- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight analysis reveals that over five key companies are actively engaged in developing more than five therapies for Netherton Syndrome.

Netherton Syndrome Overview:

Netherton Syndrome (NS) is a rare inherited disorder characterized by a triad of clinical features: a type of skin scaling called congenital ichthyosis, hair shaft abnormalities-most commonly trichorrhexis invaginata, also known as "bamboo hair"-and a strong predisposition to allergic conditions such as eczema, asthma, and allergic rhinitis. First identified by Earl Netherton in 1958, it is classified under the broader group of ichthyoses, which primarily affect the skin.

Symptoms of NS vary in severity. Newborns may present with erythroderma, where the skin appears red, scaly, and inflamed over much of the body, potentially leading to complications like dehydration, infections, and difficulty maintaining body temperature. The characteristic hair abnormality, trichorrhexis invaginata, involves the hair shaft folding inward, giving it a bamboo-like appearance under a microscope. People with NS are also highly prone to atopic dermatitis, resulting in persistent, itchy, inflamed skin that can significantly impact quality of life.

The condition is caused by mutations in the SPINK5 gene, which encodes the LEKTI protein, a serine protease inhibitor crucial for maintaining the skin barrier. When LEKTI is absent or nonfunctional due to these mutations, protease activity in the skin becomes uncontrolled. This weakens the skin's protective barrier, leading to increased water loss, higher susceptibility to infections, and abnormal shedding of skin cells, which contributes to the hallmark features of ichthyosis.

Download our report @

"Netherton Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Netherton Syndrome Therapeutics Market.

Key Takeaways from the Netherton Syndrome Pipeline Report

• DelveInsight's Netherton Syndrome pipeline report highlights a dynamic landscape with over five active companies developing more than five therapies for the treatment of NS.

• In April 2025, Quoin reported promising outcomes from an ongoing pediatric study. After six weeks of full-body application of QRX003, the first pediatric participant showed notable skin improvements along with a reduced reliance on other medications. A second patient has now been approved for full-body treatment in this trial.

• Also in April 2025, ResVita Bio announced that the FDA granted Orphan Drug Designation to RVB-003, a novel therapeutic candidate for NS, supporting its development for this rare disease.

• In December 2024, Quoin Pharmaceuticals received FDA approval to start a new clinical study evaluating QRX003, a topical lotion for NS, over more than 80% of each participant's body surface area.

• Key companies working to advance NS treatments include TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharma, and others, contributing to a promising pipeline. Notable therapies in development include QRX003, SXR-1096, and additional candidates aimed at improving patient outcomes.

Netherton Syndrome Pipeline Analysis

The Netherton Syndrome pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Netherton Syndrome Market.

• Categorizes Netherton Syndrome therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Netherton Syndrome drugs under development based on:

  • Stage of development

  • Netherton Syndrome Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Netherton Syndrome Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Netherton Syndrome Licensing agreements

  • Funding and investment activities supporting future Netherton Syndrome market advancement.

Request for a sample report @

Netherton Syndrome Emerging Drugs

• QRX003: Quoin Pharmaceuticals

• SXR-1096: Sixera Pharma

Netherton Syndrome Companies

More than five prominent companies are currently working on therapies for Netherton Syndrome, with Quoin Pharmaceuticals leading the way with a drug candidate that has reached the most advanced stage of development-Phase II/III clinical trials.

DelveInsight's report covers around 5+ products under different phases of Netherton Syndrome clinical trials like

• Netherton Syndrome Late stage Therapies (Phase III)

• Netherton Syndrome Mid-stage Therapies (Phase II)

• Netherton Syndrome Early-stage Therapies (Phase I)

• Netherton Syndrome Pre-clinical and Netherton Syndrome Discovery stage Therapies

• Netherton Syndrome Discontinued & Inactive Therapies

Netherton Syndrome pipeline report provides the Netherton Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Netherton Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Netherton Syndrome Therapies and Key Netherton Syndrome Companies: Netherton Syndrome Clinical Trials and recent advancements

Netherton Syndrome Pipeline Therapeutic Assessment

. Netherton Syndrome Assessment by Product Type

. Netherton Syndrome By Stage

. Netherton Syndrome Assessment by Route of Administration

. Netherton Syndrome Assessment by Molecule Type

Download Netherton Syndrome Sample report to know in detail about the Netherton Syndrome treatment market @ Netherton Syndrome Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Netherton Syndrome Current Treatment Patterns

4. Netherton Syndrome - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Netherton Syndrome Late-Stage Products (Phase-III)

7. Netherton Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Netherton Syndrome Discontinued Products

13. Netherton Syndrome Product Profiles

14. Netherton Syndrome Key Companies

15. Netherton Syndrome Key Products

16. Dormant and Discontinued Products

17. Netherton Syndrome Unmet Needs

18. Netherton Syndrome Future Perspectives

19. Netherton Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Netherton Syndrome Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN02092025003238003268ID1110008893